Welcome to our dedicated page for Tabula Rasa Heal news (Ticker: TRHC), a resource for investors and traders seeking the latest updates and insights on Tabula Rasa Heal stock.
Tabula Rasa HealthCare, Inc. (TRHC) generates news that reflects its focus on medication safety, pharmacy services and technology-enabled solutions for value-based care organizations. Company announcements highlight how TRHC works with health plans, at-risk provider groups and programs such as the Program of All-Inclusive Care for the Elderly (PACE) to address medication-related risks and support complex patient populations.
News coverage for TRHC often includes financial results and operational updates. Earnings releases describe trends in medication revenue and technology-enabled solutions revenue, with commentary on factors such as PACE census growth, revenue per PACE participant and changes in gross margin. These updates also discuss non-GAAP measures like adjusted EBITDA, adjusted gross profit and adjusted operating income or loss, which TRHC presents as supplemental indicators of performance.
Another key category of TRHC news involves strategic and corporate developments. The company has reported the divestiture of non-core businesses such as SinfoníaRx and DoseMe, and it announced a definitive agreement to be acquired by Nautic Partners and combined with ExactCare Pharmacy. Corporate updates have also covered leadership changes, including the appointment of a new President and Chief Executive Officer and the addition of a Chief Legal Officer and Corporate Secretary.
TRHC also issues news about client relationships and solution deployments. For example, the company announced that Mountain Empire PACE signed agreements for personalized pharmacy services and pharmacy benefit management, building on existing use of PACElogic integrated technology solutions and PeakTPA administration services. Such stories illustrate how TRHC’s offerings are applied in real-world care settings.
Investors, analysts and healthcare professionals can use this news stream to follow TRHC’s financial performance, corporate actions, partnerships and the evolution of its medication safety and pharmacy care solutions over time.
Tabula Rasa HealthCare (TRHC) has partnered with Equiscript to enhance medication adherence analytics for community health centers and hospitals. This collaboration aims to deliver detailed adherence reports and Star ratings to Equiscript’s clients, improving patient outcomes and risk mitigation. TRHC's clinical algorithms will help identify patients needing medication reviews, thus optimizing medication safety. The 340B Program underpins this initiative, aiming to maximize resources and services for eligible patients.
Tabula Rasa HealthCare (NASDAQ: TRHC) announced a partnership with Regence to conduct a virtual clinical trial assessing adverse drug events (ADEs) related to COVID-19 drug repurposing. The study will analyze de-identified data from around 500,000 Regence health plan members, employing TRHC's MedWise technology to evaluate medication risks. The results are expected within 60 days, contributing critical safety information for COVID-19 treatments. Regence serves 3.1 million members across several states, emphasizing a commitment to improving healthcare during the pandemic.
Tabula Rasa HealthCare (TRHC) has signed a Letter of Intent with ASCP to enhance medication safety for older adults. This partnership will allow ASCP's pharmacist members to access TRHC's MedWise technology, aimed at optimizing medication regimens and reducing adverse drug events. ASCP CEO Chad Worz emphasized the value of MedWise in improving care for senior patients. TRHC’s CEO, Calvin Knowlton, highlighted that the collaboration aims to cut healthcare costs and strengthen pharmacist-patient relationships while addressing medication-related issues effectively.
Tabula Rasa HealthCare (TRHC) reported its Q1 2020 financial results, showcasing total revenue of $72.8 million, a 19% increase year-over-year. This figure aligns closely with guidance expectations. However, Non-GAAP Adjusted EBITDA decreased 16% to $4.8 million, attributed to increased investments and COVID-19 related expenses. Despite these challenges, the company recorded a significant 102% increase in bookings compared to last year, driven largely by new partnerships. Revenue guidance for the full year remains steady, indicating resilience amid ongoing market uncertainties.
Summary not available.